Novartis' Galvus hits trouble in Germany
This article was originally published in Scrip
Executive Summary
Novartis' Galvus (vildagliptin) offers no extra benefit over generic sulfonylureas, according to the G-BA, the body in charge of Germany's tough AMNOG pricing and reimbursement decision. The verdict, part of first ever retrospective assessment looking at drugs that predate the AMNOG system, could lead to a big price cut for the drug, or withdrawal from the market.